Risk Factors of chronic kidney disease in HIV-infected patients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 7, 2011, Pages 1700-1707

  Flandre, Philippe ^a,b   Pugliese, Pascal ^c   Cuzin, Lise ^d   Bagnis, Corinne Isnard ^e   Tack, Ivan ^f   Cabié, André ^g   Poizot Martin, Isabelle ^h   Katlama, Christine ^b   Brunet François, Cécile ⁱ   Yazdanpanah, Yazdan ^j   Dellamonica, Pierre ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d CHU PURPAN   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f CHU RANGUEIL   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^h HÔPITAL SAINTE MARGUERITE   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER DE TOURCOING   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CREATININE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RNA; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTI-RETROVIRAL AGENTS; CHRONIC DISEASE; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79960331112     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09191010     Document Type: Article

References (42)

1. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD: HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 42: 1488-1495, 2006
2. Cheung CY, Wong KM, Lee MP, Liu YL, Kwok H, Chung R, Chau KF, Li CK, Li CS: Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant 22: 3186-3190, 2007
3. Fernando SK, Finkelstein FO, Moore BA, Weissman S: Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 335: 89-94, 2008
4. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD: End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 21: 2435-2443, 2007
5. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD: Chronic renal failure among HIV-1-infected patients. AIDS 21: 1119-1127, 2007
6. Gagnon RF, Tecimer SN, Watters AK, Tsoukas CM: Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 36: 507-515, 2000
7. Brewster UC, Perazella MA: Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 44: e81-e84, 2004
8. Chugh S, Bird R, Alexander EA: Ritonavir and renal failure. N Engl J Med 336: 138, 1997
9. Duong M, Sgro C, Grappin M, Biron F, Boibieux A: Renal failure after treatment with ritonavir. Lancet 348: 693, 1996
10. James CW, Steinhaus MC, Szabo S, Dressier RM: Tenofovirrelated nephrotoxicity: Case report and review of the literature. Pharmacotherapy 24: 415-418, 2004
11. Rifkin BS and Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 117: 282-284, 2004
12. Perazella MA: Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 325: 349-362, 2003
13. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Céron D: Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273, 2004
14. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G: Drug-induced Fanconi's syndrome. Am J Kidney Dis 41: 292-309, 2003
15. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M: Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: A case of drug-drug interaction. Clin Nephrol 71: 567-570, 2009
16. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165-1173, 2007
17. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
18. Pugliese P, Cuzin L, Cabie A, Poizot-Martin I, Allavena C, Duvivier C, El Guedj M, de la Tribonnière X, Valantin MA, Dellamonica P; Nadis Group. A large French prospective cohort of HIV-infected patients: The Nadis Cohort. HIV Med 10: 504-511, 2009
19. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005
20. Gupta S, Eustace J, Winston J, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA: Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 1559-1585, 2005
21. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40: 1194-1198, 2005
22. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV: The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163, 2008
23. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM: Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 22: 481-487, 2008
24. Campbell L, Ibrahim F, Fisher M, Holt S, Hendry B, Post F: Spectrum of chronic kidney disease in HIV-infected patients. HIV Medicine 10: 329-336, 2009
25. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr., Klein D. Impact of Tenofovir on Renal Function in HIV-Infected Antiretroviral Naive Patients. J Acquir Immune Defic Syndr 53: 62-69, 2009
26. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA: HIV care and the incidence of acute renal failure. Clin Infect Dis 47: 242-249, 2008
27. Sorli ML, Guelar A, Montero M, Gonzalez A, Rodriguez E, Knobel H: Chronic kidney disease prevalence and risk factors among HIV-infected patients. J Acquir Immune Defic Syndr 48: 506-508, 2008
28. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G, Study 903 Team. Longterm renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients: Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20: 743-746, 2005
29. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 371: 1417-1426, 2008
30. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG: Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 24: 387-394, 2010
31. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20: 2043-2050, 2006
32. Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin G,: Jr. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 18: 2171-2178, 2004
33. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG: HIV viremia and changes in kidney function. AIDS 23: 1089-1096, 2009
34. Levey AS: Measurement of renal function in chronic renal disease. Kidney Int 38: 167-184, 1990
35. Striker GE, Schainuck LI, Cutler RE, Benditt EP: Structuralfunctional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol 1: 615-630, 1970
36. Ravasi G, Lauriola M, Tinelli C, Brandolini M, Uglietti A, Maserati R: Comparison of glomerular filtration rate estimates vs. 24-h creatinine clearance in HIV-positive patients. HIV Med 10: 219-228, 2009
37. Barraclough K, Er L, Ng F, Harris M, Montaner J, Levin A: A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 111: c39-c48, 2009
38. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM: Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21: 1431-1439, 2007
39. Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I: Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS 23: 257-259, 2009
40. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, González-Pardo G, Khoo S, Back D, Owen A: Predictors of kidney tubular dysfunction in HIVinfected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-e116, 2009
41. Kinai E, Hanabusa H: Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 19: 2031-2033, 2005
42. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, Vispo E, Soriano V: Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23: 689-696, 2009